Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | FASN | P49327 | 12/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5885818 | 0.85 | ACACB (0.46) | ACACBHPGDHTT | |
| Hydrochloric Acid SCHEMBL5885902 | 0.85 | ACACB (0.46) | ACACBHPGDHTT | |
| SCHEMBL5885749 | 0.84 | ACACB (0.48) | ACACBCCKBR | |
| SCHEMBL6556808 | 0.81 | ACACB (0.53) | ACACBCCKBRFASNHPGDPOLB | |
| SCHEMBL6563683 | 0.81 | DPP7 (0.49) | ACACBFASN | |
| SCHEMBL6563806 | 0.77 | ACACB (0.52) | ACACBHPGDPOLBHTT | |
| SCHEMBL5885873 | 0.77 | ACACB (0.57) | ACACBHPGDHTT | |
| SCHEMBL6563753 | 0.76 | ACACB (0.56) | ACACBHPGDHTT | |
| SCHEMBL6563935 | 0.76 | ACACB (0.48) | ACACBFASNHPGDPOLBAR | |
| SCHEMBL5885408 | 0.75 | ACACB (0.46) | ACACBCCKBRPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005437-B2 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-02-28 | — | — | US | disclosed |
| EP-1404648-A1 | AMIDINE SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES WITH AN ANTITHROMBOTIC AND FACTOR XA INHIBITING ACTION | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003101942-A1 | AMIDINE SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES WITH AN ANTITHROMBOTIC AND FACTOR XA INHIBITING ACTION | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-11 | — | — | WO | disclosed |
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | F2, F12, F3 | ACACB 2639/4885CCKBR 1367/4885FASN 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.